The Effectiveness of Ologen® Collagen Matrix in Preventing Intraocular Pressure (IOP) Spikes After Ahmed Glaucoma Valve Surgery (AGV-FP7)
Primary Purpose
Glaucoma
Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Ologen
Sponsored by
About this trial
This is an interventional treatment trial for Glaucoma
Eligibility Criteria
Inclusion Criteria:
- Age ≥18 years.
- Uncontrolled treated glaucoma requiring AGV-FP7 surgery.
- Subject must be able and willing to cooperate with investigation plan.
- Subject must be able and willing to complete postoperative follow-up requirements
- Subject must be willing to sign informed consent form
Exclusion Criteria:
- Known allergic reaction to porcine collagen
- History of uveitis
- Corneal opacity or irregularity, preventing visualization of patency of tip of tube or accurate applanation
- History of scleral buckle
Sites / Locations
- New York Eye and Ear Infirmary
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Active Comparator
Arm Label
Glaucoma Drainage implant no Ologen
Glaucoma Drainage implant with Ologen
Arm Description
The first group will use the routine technique for glaucoma drainage implant without placement of Ologen.
the second group will undergo the same procedure but will have the Ologen placed and secured over the plate of the AGV-FP7, under the conjunctiva, during the surgery.
Outcomes
Primary Outcome Measures
The Effectiveness of ologen® Collagen Matrix in preventing intraocular pressure (IOP) spikes after Ahmed Glaucoma Valve Surgery (AGV-FP7)
Ologen over the posterior plate of the Ahmed glaucoma drainage device during initial implantation will allow the formation of a thinner capsule, and decrease the incidence and/or the extent of IOP elevation during the postoperative period.
Secondary Outcome Measures
Full Information
NCT ID
NCT02990143
First Posted
December 6, 2016
Last Updated
March 15, 2021
Sponsor
The New York Eye & Ear Infirmary
1. Study Identification
Unique Protocol Identification Number
NCT02990143
Brief Title
The Effectiveness of Ologen® Collagen Matrix in Preventing Intraocular Pressure (IOP) Spikes After Ahmed Glaucoma Valve Surgery (AGV-FP7)
Official Title
The Effectiveness of Ologen® Collagen Matrix in Preventing Intraocular Pressure (IOP) Spikes After Ahmed Glaucoma Valve Surgery (AGV-FP7)
Study Type
Interventional
2. Study Status
Record Verification Date
March 2021
Overall Recruitment Status
Terminated
Why Stopped
Investigator left the Institution
Study Start Date
January 15, 2014 (Actual)
Primary Completion Date
December 15, 2017 (Actual)
Study Completion Date
December 15, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The New York Eye & Ear Infirmary
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to investigate whether placing Ologen over the posterior plate of the Ahmed glaucoma drainage device during initial implantation will allow the formation of a thinner capsule, and decrease the incidence and/or the extent of IOP elevation during the postoperative period.
Detailed Description
Uncontrolled glaucoma may require surgical intervention. Glaucoma drainage implants such as AGV-FP7 are in wide use upon glaucoma and comprehensive surgeons. The success of aqueous shunt surgery depends on the formation and maintenance of a thin permeable capsule around the posterior plate of the aqueous shunt. Encapsulated bleb formation, where the capsule is thick and elevated, is a common cause of drainage failure in the early post-operative period. This finding is usually accompanied by elevated intraocular pressure (IOP), which requires additional intervention, often surgical and therefore reduces the success rate of the initial surgery.
Recently, a biodegradable porous collagen-glycosaminoglycan copolymer matrix implant (Ologen), has become available for glaucoma surgery. This device is constructed so as to minimize random growth of fibroblasts and instead to allow them to grow through the pores in the matrix. Ologen® CM,a biodegradable scaffold matrix, induces a regenerative non-scarring wound healing process without using anti-fibrotic agents.
This study is to investigate whether placing Ologen over the posterior plate of the Ahmed glaucoma drainage device during initial implantation will allow the formation of a thinner capsule, and decrease the incidence and/or the extent of IOP elevation during the postoperative period.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glaucoma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Glaucoma Drainage implant no Ologen
Arm Type
No Intervention
Arm Description
The first group will use the routine technique for glaucoma drainage implant without placement of Ologen.
Arm Title
Glaucoma Drainage implant with Ologen
Arm Type
Active Comparator
Arm Description
the second group will undergo the same procedure but will have the Ologen placed and secured over the plate of the AGV-FP7, under the conjunctiva, during the surgery.
Intervention Type
Procedure
Intervention Name(s)
Ologen
Intervention Description
Ologen® CM,a biodegradable scaffold matrix, induces a regenerative non-scarring wound healing process without using anti-fibrotic agents.
Primary Outcome Measure Information:
Title
The Effectiveness of ologen® Collagen Matrix in preventing intraocular pressure (IOP) spikes after Ahmed Glaucoma Valve Surgery (AGV-FP7)
Description
Ologen over the posterior plate of the Ahmed glaucoma drainage device during initial implantation will allow the formation of a thinner capsule, and decrease the incidence and/or the extent of IOP elevation during the postoperative period.
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age ≥18 years.
Uncontrolled treated glaucoma requiring AGV-FP7 surgery.
Subject must be able and willing to cooperate with investigation plan.
Subject must be able and willing to complete postoperative follow-up requirements
Subject must be willing to sign informed consent form
Exclusion Criteria:
Known allergic reaction to porcine collagen
History of uveitis
Corneal opacity or irregularity, preventing visualization of patency of tip of tube or accurate applanation
History of scleral buckle
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Noga Harizman, MD
Organizational Affiliation
NY Eye Ear
Official's Role
Principal Investigator
Facility Information:
Facility Name
New York Eye and Ear Infirmary
City
New York
State/Province
New York
ZIP/Postal Code
10003
Country
United States
12. IPD Sharing Statement
Learn more about this trial
The Effectiveness of Ologen® Collagen Matrix in Preventing Intraocular Pressure (IOP) Spikes After Ahmed Glaucoma Valve Surgery (AGV-FP7)
We'll reach out to this number within 24 hrs